Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs

Pharmacology & Therapeutics(2022)10.1016/j.pharmthera.2022.108162Source: DataRank Database

Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs is a research paper published in Pharmacology & Therapeutics (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.55)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Arthur J. Van De Vyver ORCID,Yu Li ORCID,Marc R. Birtwistle ORCID,Nevan J. Krogan ORCID,Mehdi Bouhaddou ORCID

Live enrichment

PubMed:35189161 PMC:PMC9292061 OpenAlex:https://openalex.org/W4212858046

National Institutes of Health

Grant: F32CA239333

National Institutes of Health

Grant: U54CA209891

NIGMS NIH HHS

Grant: R35 GM141891

National Institutes of Health

Grant: 5F32CA239333-03

Systematic Targeting of Oncogene Interacting Proteins to Reveal New Therapeutic Strategies

National Institutes of Health

Grant: 5U54CA209891-03

Research Center for Cancer Systems Biology: Cancer Cell Map Initiative

F. Hoffmann-La Roche Ltd

FWCI

0.55

Citation Percentile

0.6%

Citation Trend

2023

2024

2025

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9292061

publisherhttps://api.elsevier.com/content/article/PII:S0163725822000560?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0163725822000560?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.pharmthera.2022.108162

Fields of Study

Epigenetics and DNA MethylationHistone Deacetylase Inhibitors ResearchProtein Degradation and Inhibitors0301 basic medicine0303 health sciences03 medical and health sciencesComputer SimulationDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsEpigenesis, GeneticHumansModels, Biological

MeSH Terms

Computer SimulationDose-Response Relationship, DrugHumansModels, BiologicalEpigenesis, GeneticDrug-Related Side Effects and Adverse Reactions

Keywords

EpigeneticsDosingRegimenAdverse effectPopulationDrugNeutropeniaMedicinePharmacologyBioinformaticsOncologyBiologyToxicityInternal medicineGeneticsGeneClinical Utilitymodeling and simulationTherapeutic WindowPharmacokinetic/pharmacodynamicEpigenetic DrugsOptimized Dosing RegimenDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsHumansComputer SimulationModels, BiologicalEpigenesis, Genetic

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being